1117 related articles for article (PubMed ID: 11441305)
1. [Tumor angiogenesis: new approaches to cancer therapy].
Marmé D
Onkologie; 2001 Feb; 24 Suppl 1():1-5. PubMed ID: 11441305
[TBL] [Abstract][Full Text] [Related]
2. Two independent mechanisms essential for tumor angiogenesis: inhibition of human melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor pathway or the Tie-2 pathway.
Siemeister G; Schirner M; Weindel K; Reusch P; Menrad A; Marmé D; Martiny-Baron G
Cancer Res; 1999 Jul; 59(13):3185-91. PubMed ID: 10397264
[TBL] [Abstract][Full Text] [Related]
3. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
Wood JM
Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
[TBL] [Abstract][Full Text] [Related]
5. Differential inhibition of tumor angiogenesis by tie2 and vascular endothelial growth factor receptor-2 dominant-negative receptor mutants.
Stratmann A; Acker T; Burger AM; Amann K; Risau W; Plate KH
Int J Cancer; 2001 Feb; 91(3):273-82. PubMed ID: 11169947
[TBL] [Abstract][Full Text] [Related]
6. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model.
Drevs J; Hofmann I; Hugenschmidt H; Wittig C; Madjar H; Müller M; Wood J; Martiny-Baron G; Unger C; Marmé D
Cancer Res; 2000 Sep; 60(17):4819-24. PubMed ID: 10987292
[TBL] [Abstract][Full Text] [Related]
7. Tumor-specific regulation of angiogenic growth factors and their receptors during recovery from cytotoxic therapy.
Taylor AP; Osorio L; Craig R; Raleigh JA; Ying Z; Goldenberg DM; Blumenthal RD
Clin Cancer Res; 2002 Apr; 8(4):1213-22. PubMed ID: 11948135
[TBL] [Abstract][Full Text] [Related]
8. Anti-angiogenic treatment strategies for malignant brain tumors.
Kirsch M; Schackert G; Black PM
J Neurooncol; 2000; 50(1-2):149-63. PubMed ID: 11245274
[TBL] [Abstract][Full Text] [Related]
9. Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer.
Zhang L; Yang N; Park JW; Katsaros D; Fracchioli S; Cao G; O'Brien-Jenkins A; Randall TC; Rubin SC; Coukos G
Cancer Res; 2003 Jun; 63(12):3403-12. PubMed ID: 12810677
[TBL] [Abstract][Full Text] [Related]
10. Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth.
Hess C; Vuong V; Hegyi I; Riesterer O; Wood J; Fabbro D; Glanzmann C; Bodis S; Pruschy M
Br J Cancer; 2001 Dec; 85(12):2010-6. PubMed ID: 11747347
[TBL] [Abstract][Full Text] [Related]
11. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features.
Bunone G; Vigneri P; Mariani L; Butó S; Collini P; Pilotti S; Pierotti MA; Bongarzone I
Am J Pathol; 1999 Dec; 155(6):1967-76. PubMed ID: 10595926
[TBL] [Abstract][Full Text] [Related]
12. Antiangiogenic therapy targeting factors that enhance endothelial cell survival.
Liu W; Reinmuth N; Stoeltzing O; Parikh AA; Fan F; Ahmad SA; Jung YD; Ellis LM
Semin Oncol; 2002 Jun; 29(3 Suppl 11):96-103. PubMed ID: 12138403
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical study of VEGF, angiopoietin 2 and their receptors in the neovascularization following microinjection of C6 glioma cells into rat brain.
Péoch M; Farion R; Hiou A; Le Bas JF; Pasquier B; Rémy C
Anticancer Res; 2002; 22(4):2147-51. PubMed ID: 12174896
[TBL] [Abstract][Full Text] [Related]
14. Angiopoietin inhibitors: A review on targeting tumor angiogenesis.
Parmar D; Apte M
Eur J Pharmacol; 2021 May; 899():174021. PubMed ID: 33741382
[TBL] [Abstract][Full Text] [Related]
15. PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging.
Drevs J; Müller-Driver R; Wittig C; Fuxius S; Esser N; Hugenschmidt H; Konerding MA; Allegrini PR; Wood J; Hennig J; Unger C; Marmé D
Cancer Res; 2002 Jul; 62(14):4015-22. PubMed ID: 12124335
[TBL] [Abstract][Full Text] [Related]
16. Microtumor growth initiates angiogenic sprouting with simultaneous expression of VEGF, VEGF receptor-2, and angiopoietin-2.
Vajkoczy P; Farhadi M; Gaumann A; Heidenreich R; Erber R; Wunder A; Tonn JC; Menger MD; Breier G
J Clin Invest; 2002 Mar; 109(6):777-85. PubMed ID: 11901186
[TBL] [Abstract][Full Text] [Related]
17. VEGF receptor signaling in tumor angiogenesis.
McMahon G
Oncologist; 2000; 5 Suppl 1():3-10. PubMed ID: 10804084
[TBL] [Abstract][Full Text] [Related]
18. Tie-1: A potential target for anti-angiogenesis therapy.
Yang P; Chen N; Jia JH; Gao XJ; Li SH; Cai J; Wang Z
J Huazhong Univ Sci Technolog Med Sci; 2015 Oct; 35(5):615-622. PubMed ID: 26489611
[TBL] [Abstract][Full Text] [Related]
19. Endothelial survival factors as targets for antineoplastic therapy.
Reinmuth N; Stoeltzing O; Liu W; Ahmad SA; Jung YD; Fan F; Parikh A; Ellis LM
Cancer J; 2001; 7 Suppl 3():S109-19. PubMed ID: 11779081
[TBL] [Abstract][Full Text] [Related]
20. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
Gacche RN; Meshram RJ
Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
